Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
NCT04157491
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Endometrial Cancer
Interventions
DRUG:
anlotinib and anti PD-1 antibody
Sponsor
Sun Yat-sen University